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Abstract
Aims—Sildenafil is frequently prescribed to children with single ventricle heart defects. These 
children have unique hepatic physiology with elevated hepatic pressures which may alter drug 
pharmacokinetics. We sought to determine the impact of hepatic pressure on sildenafil 
pharmacokinetics in children with single ventricle heart defects.
Methods—A population pharmacokinetic model was developed using data from 20 single 
ventricle children receiving single dose intravenous sildenafil during cardiac catheterization. 
Nonlinear mixed effect modeling was used for model development and covariate effects were 
evaluated based on estimated precision and clinical significance.
Results—The analysis included a median (range) of 4 (2–5) pharmacokinetic samples per child. 
The final structural model was a two-compartment model for sildenafil with a one-compartment 
model for des-methyl-sildenafil (active metabolite), with assumed 100% sildenafil to des-methyl-
sildenafil conversion. Sildenafil clearance was unaffected by hepatic pressure (clearance = 0.62 
L/H/kg); however, clearance of des-methyl-sildenafil (1.94 × (hepatic pressure/9)−1.33 L/h/kg) was 
predicted to decrease ~7 fold as hepatic pressure increased from 4 to 18 mm Hg. Predicted drug 
exposure was increased by ~1.5 fold in subjects with hepatic pressures ≥ 10 mm Hg versus < 10 
mm Hg (median area under the curve = 533 μg*h/L versus 792 μg*h/L).
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Discussion—Elevated hepatic pressure delays clearance of the sildenafil metabolite, des-
methyl-sildenafil and increases drug exposure. We speculate that this results from impaired biliary 
clearance. Hepatic pressure should be considered when prescribing sildenafil to children. These 
data demonstrate the importance of pharmacokinetic assessment in patients with unique 
cardiovascular physiology that may affect drug metabolism.
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INTRODUCTION
Population pharmacokinetics refers to the study of drug kinetics in target populations with 
unique pathophysiology that might affect the drug dose-concentration relationship.1 
Children with palliated single ventricle heart defects have very unique physiology including 
a propensity for elevated venous/hepatic pressures with associated hepatic congestion. These 
factors may alter drug pharmacokinetics, particularly for drugs undergoing hepatic 
metabolism and therefore these patients represent an ideal population for population 
pharmacokinetic assessment.2–7
Sildenafil is a phosphodiesterase type-5 inhibitor that is often used to lower pulmonary 
vascular resistance in children and adults with single ventricle heart defects.8–11 Sildenafil 
undergoes predominantly hepatic metabolism (cytochrome P450 3A4 [major route] and 
cytochrome P450 2C9 [minor route]) and is converted to an active metabolite, des-methyl-
sildenafil, which has approximately 50% of the in vitro potency for phosphodiesterase 
type-5 as the parent drug.12 In adult patients with hepatic congestion secondary to 
pulmonary arterial hypertension or hepatic dysfunction (e.g. cirrhosis), sildenafil clearance 
is reduced by 50–80% with effects on clearance of both sildenafil and des-methyl-
sildenafil.13 Although single ventricle patients frequently demonstrate hepatic dysfunction 
and congestion, no prior studies have evaluated sildenafil pharmacokinetics in single 
ventricle patients. Sildenafil dosing in children has been the source of recent controversy 
after the “sildenafil in Treatment-Naive Children, Aged 1–17 Years, with Pulmonary 
Arterial Hypertension” (STARTS) trials demonstrated increased mortality in children with 
pulmonary hypertension randomized to medium or high dose sildenafil when compared to 
low dose therapy.14,15
In the present study we sought to determine the pharmacokinetics of intravenous sildenafil 
in children with surgically palliated single ventricle heart defects. We tested the hypothesis 
that clearance of sildenafil and des-methyl-sildenafil would be directly related to surgical 
stage and hepatic pressures.
MATERIALS AND METHODS
Study Population
The study design, samples analysis (limits of quantification = 0.05 μg/L) and detailed cohort 
demographics have been previously described.16,17 Briefly, blood samples were collected as 
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part of a prospective dose escalation pharmacokinetic and hemodynamic efficacy study of 
intravenous sildenafil. Children ages 6 months – 10 years and status post stage II or stage III 
single ventricle surgical palliation and undergoing electively scheduled cardiac 
catheterization were eligible for inclusion. Children with significant hepatic dysfunction 
defined as either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ two 
times the upper limits of normal were excluded from participation. Dosing groups included 
0.125 mg/kg (n=2), 0.25 mg/kg (n=5), 0.35mg/kg (n=8) and 0.45 mg/kg (n=5). The study 
was approved by the Duke University Medical Center Institutional Review Board and 
written informed consent for trial participation was obtained from the parent or guardian of 
each study subject.
Population PK model development
Sildenafil and des-methyl-sildenafil concentration-time data were analyzed using nonlinear 
mixed effects modeling with Phoenix NLME 1.2 software (Certara, St. Louis, MO) using 
the first order conditional estimation with interaction algorithm. One, two, and three-
compartment structural pharmacokinetic models for sildenafil and des-methyl-sildenafil, 
100% conversion of sildenafil to des-methyl-sildenafil (represented by clearance sildenafil 
to des-methyl-sildenafil) or <100% conversion (represented by clearance sildenafil to des-
methyl-sildenafil in addition to a sildenafil elimination clearance parameter), and 
proportional versus proportional plus additive residual error models were explored.
Random effects on structural model parameters were considered supported by the data if 
shrinkage was <30% and condition number was <1000. Weight was included a priori as 
covariates for structural model parameters, using a fixed (3/4 or 1) or estimated exponent. 
Diagnostic plots used for model evaluation included the following: observed versus 
population predicted concentration and versus individual predicted concentration; 
conditional weighted residuals versus population predicted concentration and versus time 
after last dose; random effects and conditional weighted residuals histograms; and observed 
versus population predicted and individual predicted concentrations by patient. In addition, 
precision of parameter estimates and objective function values were used to assess model 
goodness-of-fit.
Once the base model was selected, covariates were investigated for their influence on 
pharmacokinetic parameters. Continuous covariates evaluated were age, weight, cardiac 
index (calculated from catheterization data at the time of sildenafil administration), serum 
creatinine, and hepatic pressure (directly measured at the time of sildenafil administration) 
and were centered around the median. Categorical covariates included surgical stage, race, 
and sex. In the final model, comparisons were made between subjects with hepatic pressures 
≥ 10mm Hg versus those with hepatic pressures < 10mm Hg based on an a-priori estimation 
of the approximate cutpoint for abnormal hepatic (central venous) pressures in children of 
similar age. Inter-individual variability estimates in pharmacokinetic parameters were 
plotted against covariates, and those with a discernible physiologic and graphical 
relationship were evaluated for inclusion in the final model. The threshold for significance 
of a single covariate was reduction of the objective function by >3.84 (p < 0.05). A forward-
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addition (p = 0.05), backward-elimination (p = 0.01) approach to covariate selection was 
planned for use if more than one covariate were found to be significant.
Model evaluation
Base and final model performance was evaluated based on successful minimization, 
goodness-of-fit plots, and precision of parameter estimates. The final model was further 
evaluated with bootstrap procedures and visual predictive check. The precision of the final 
population pharmacokinetic model parameter estimates were evaluated using nonparametric 
bootstrapping (1,000 replicates) to generate the 95% confidence intervals for parameter 
estimates. For the visual predictive check, the final model was used to generate 1,000 Monte 
Carlo simulation replicates of sildenafil exposure, and simulated results were compared with 
those observed in the study. The number of observed concentrations outside the 90% 
prediction interval for each time point was quantified.
Dose-exposure assessment
Individual pharmacokinetic parameters from the final model were used to simulate sildenafil 
and des-methyl-sildenafil concentration-time profiles after a single dose. Using Phoenix 
WinNonlin 6.3 software and simulated concentration-time profiles, elimination rate 
constants were calculated from linear regression of log concentration versus time in the 
elimination phase, area under the curve was calculated using the trapezoidal rule and linear 
up log down method, and elimination half-life (t1/2) was calculated as ln(2)/elimination rate 
constant assuming linear kinetics. As des-methyl-sildenafil has 50% activity compared to 
sildenafil, combined area under the curve was calculated as: (sildenafil area under the curve) 
+ ([des-methyl-sildenafil area under the curve]/2).
RESULTS
Twenty children were enrolled in the study. Indications for cardiac catheterization included: 
pre-Fontan evaluation (n=9), hemodynamic assessment secondary to relative cyanosis (n=3), 
pulmonary artery evaluation (n=4), poor function by echocardiogram (n=2), aortic arch 
evaluation (n=1) or suspected high pulmonary vascular resistance (n=1). Demographic 
features and physiologic parameters are summarized by dosing group in Table 1.
Overall, 140 samples (73 sildenafil and 67 des-methyl-sildenafil) were above the limits of 
quantification (0.05 μg/L) and 20 (7 sildenafil, 13 des-methyl-sildenafil) were below. One 
outlier peak sildenafil concentration and all samples below the limits of quantification were 
excluded. Thus, the analysis included 72 sildenafil and 67 des-methyl-sildenafil samples 
from 20 children. The median (range) number of sildenafil and des-methyl-sildenafil 
samples per child was 4 (2–5) and 3.5 (2–5). The median (IQR) sildenafil and des-methyl-
sildenafil sampling times for the 1st, 2nd, 3rd, 4th and 5th samples were 20 (20, 20) min, 60 
(43, 64) min; 1.9 (1.4, 3.0) hours, 4.1 (1.8, 5.1) hours and 18.8 (17.3, 20.8) hours after dose, 
respectively. Concentration-time profiles stratified by surgical stage are shown in Figure 1. 
The median (range) sildenafil and des-methyl-sildenafil concentrations were 106 (1.59–775) 
and 16.6 (1.08 – 96.2) μg/L, respectively.
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Population pharmacokinetic model development
Figure 2 summarizes the final structural model which was a two-compartment model for 
sildenafil, one-compartment model for des-methyl-sildenafil, with assumed 100% sildenafil 
to des-methyl-sildenafil conversion, and metabolite clearance from the body represented by 
des-methyl-sildenafil clearance. The data only supported the addition of inter-individual 
variability parameters for sildenafil to des-methyl-sildenafil conversion and des-methyl-
sildenafil clearance (i.e. shrinkage <30%). Body weight was included as a covariate for all 
base model parameters; addition of an allometric scaling (exponent = ¾) was not included as 
it did not improve the model fit (decrease in objective function value of −1.7).
Data describing model building steps and model evaluation are included in the on-line 
supplement. In the base model, surgical stage demonstrated a suggestive graphical 
relationship to inter-individual variability for conversion of sildenafil to des-methyl-
sildenafil. Gender, surgical stage and mean hepatic pressure demonstrated a suggestive 
graphical relationship for inter-individual variability for des-methyl-sildenafil clearance 
(Supplementary Figure 1). By univariable screen, mean hepatic pressure and surgical stage 
were significant covariates for des-methyl-sildenafil clearance; after inclusion of hepatic 
pressure, no additional covariates were significant (Supplementary Figure 2 and 
Supplementary Table 1). Body weight was used as a covariate for all final model 
parameters. The final model demonstrated adequate goodness-of-fit with no significant 
deviation from the unity line for sildenafil model-predictions versus observed concentrations 
and no significant deviation from zero for residuals (Supplementary Figure 3A–D). There 
was under-prediction of the highest des-methyl-sildenafil concentrations found in surgical 
stage 3 children (Supplementary Figure 4A–B), and absence of bias in residuals 
(Supplementary Figure 4C–D).
Model evaluation—The number of observed concentrations outside the visual predictive 
check 90% prediction interval for sildenafil and des-methyl-sildenafil were 6/72 (8%) and 
8/67 (12%) respectively, indicating good model predictive performance (Supplementary 
Figure 5). Relative standard errors of bootstrapped parameter estimates were <20%, and the 
percent difference between model and bootstrapped median parameter estimates was ≤5% 
(with the exception of the correlation coefficient), indicating precise estimation of 
population model parameters (Supplementary Table 2).
Dose-exposure assessment—Individual Bayesian parameter estimates are included in 
Table 2. As suggested by the final model, clearance of des-methyl-sildenafil was decreased 
and des-methyl-sildenafil half-life (t1/2) increased in children with HP ≥10 mm Hg. 
Following a single dose of 0.35 mg/kg and using individual Bayesian PK parameter 
estimates, predicted area under the curve for sildenafil, des-methyl-sildenafil and combined 
for the study population increased with increasing HP (Figure 3A–C). Median (range) 
predicted combined area under the curve was 533 μg*h/L [284 – 1046] and 792 μg*h/L [417 
– 1431] (~1.5-fold difference) for children with hepatic pressure <10 mm Hg and ≥10 mm 
Hg, respectively. Following the same single dose of 0.35 mg/kg in children with hepatic 
pressure <10 mm Hg and 0.25 mg/kg in children with HP >10 mm Hg, median (range) 
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predicted AUCTOTAL was similar between dose groups (533 μg*h/L [284 – 1046] and 565 
[298 – 1022] μg*h/L, respectively [Figure 3D–F]).
DISCUSSION
This is the first population pharmacokinetic analysis of intravenous sildenafil in children and 
the first population pharmacokinetic analysis of any kind in children or adults with palliated 
single ventricle heart defects. These patients have very unique physiology often 
demonstrating chronically elevated central venous pressures and secondary hepatic 
congestion.4–6 We demonstrate delayed clearance of the active sildenafil metabolite, des-
methyl-sildenafil, with a direct relationship to increased hepatic pressures. The 
consequences are potentially clinically important with an estimated 1.5-fold increase in drug 
exposure (area under the curve) in subjects with hepatic pressures ≥ 10 mm Hg when 
compared to those with hepatic pressures < 10 mm Hg.
The only previous study of intravenous sildenafil in the pediatric population focused on term 
neonates with persistent pulmonary hypertension of the newborn, demonstrating typical 
clearance and volume of distribution at steady state (central + peripheral) for a three day old 
neonate of 0.54 L/h/kg and 7.8 L/kg, respectively.18 Studies in adults with pulmonary 
hypertension have reported approximate weight-normalized clearance of 0.38 – 0.59 L/h/kg 
with, a half-life of 2.2 – 3.9 h.19–21 The sildenafil value of 0.62 L/h/kg reported in this study 
is similar to clearance values in the healthy adult (0.59 L/h/kg) and neonatal studies (0.54 
L/h/kg). Based on allometric scaling, we anticipated higher weight-normalized clearance 
values in children relative to adults. However, the altered physiology and morbidity related 
to single ventricle physiology may result in the lower than expected sildenafil clearance that 
we observed.
Interestingly, we detected a covariate effect of increased hepatic pressure on clearance of 
des-methyl-sildenafil, but not for clearance of sildenafil itself. According to the model, for a 
child of given weight, des-methyl-sildenafil clearance is predicted to decrease ~7 fold as 
hepatic pressure increases from 4 to 18 mm Hg. We hypothesize that increased hepatic 
pressure selectively impaired des-methyl-sildenafil clearance as a result of decreased biliary 
clearance. In mouse, rat, and dog, des-methyl-sildenafil is excreted to bile and found in 
feces, while sildenafil is cleared primarily by metabolism.12,22 Potentially selectively 
impaired des-methyl-sildenafil clearance due to increased hepatic pressure could be 
explained by unimpaired access of sildenafil to sites of metabolism in hepatocytes, but 
impaired des-methyl-sildenafil clearance through bile (secondary to increased hepatic 
pressure). This is consistent with a study in adults comparing oral sildenafil kinetics in 
subjects with and without liver cirrhosis. Cirrhotic subjects demonstrated reduced 
metabolism and clearance of both sildenafil and des-methyl-sildenafil but the effect was 
more substantial for des-methyl-sildenafil (48% reduction in clearance for des-methyl-
sildenafil versus 24% for sildenafil).13 Potentially sildenafil clearance was unaffected in the 
present study because hepatic blood flow is not sufficiently affected in the range of hepatic 
pressure in our study cohort. Sildenafil is an intermediate to high extraction ratio drug with 
clearance of 41 L/h following intravenous administration in healthy adults19, compared to 
typical liver blood flow of 90 L/h. As such, we would expect sildenafil clearance to be 
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potentially impacted only if increased hepatic pressure resulted in significantly decreased 
liver blood flow. However the small sample size could also play a role in our inability to 
detect a relationship between sildenafil clearance and elevated hepatic pressure. Also, none 
of our subjects demonstrated overt liver dysfunction as we excluded those with levels of 
either AST or ALT ≥ twice the upper limits of normal and only two study subjects 
demonstrated a value for either AST or ALT that was outside the normal reference range.
It is notable that inclusion of surgical stage in addition to hepatic pressures did not 
significantly change our overall model. Stage III surgical palliation significantly alters 
venous physiology, typically raising central venous and hepatic pressures.2,8 However stage 
II patients can demonstrate elevated hepatic pressures as a result of impaired ventricular 
diastolic function and our results indicate that in these patients, sildenafil dosing should be 
adjusted to account for reduced clearance. These findings have broader implications for both 
children and adults with pulmonary hypertension where central venous and hepatic pressures 
may also be substantially elevated. Potentially sildenafil dosing in these patients might also 
require adjustment based on degree of elevation in hepatic pressures.
Beyond clearance, volume of distribution and half-life are also critical determinants of drug 
kinetics. Sildenafil is likely distributed to tissues and our data demonstrate a similar volume 
of distribution relative to adults. In previous studies in healthy adults, volume of distribution 
has been reported as ~105 L21, compared to typical total body water of approximately 42 L. 
Weight-normalized total volume of distribution in the present study (1.81 L/kg) was within 
20% of volume of distribution reported in the above adult studies (~1.5 L/kg), but was ~5-
fold lower than reported in neonates.18 This finding is consistent with elevated total body 
water in neonates relative to children and adults. Similarly the sildenafil half-life reported in 
this study (median 2.9 h) is also within the range observed in healthy adults (2.2 – 3.9 h) but 
is substantially below that reported for neonates (48–56 h). Consistent with the association 
of increased hepatic pressure and reduced des-methyl-sildenafil clearance found in this 
study, des-methyl-sildenafil half-life in this study (median 3.3 h) was prolonged relative to 
healthy adults (2.3 h).19
Overall our pharmacokinetic data demonstrate the critical importance of population-specific 
pharmacokinetic assessment, particularly in patients with unique physiology that may affect 
drug metabolism. Population pharmacokinetic using sparse sampling methodologies have 
been widely applied to other patient populations but have not been commonly used in 
children with heart disease.23–26 Single ventricle patients are increasingly treated with 
sildenafil to lower pulmonary vascular resistance.8–11 We have previously demonstrated that 
intravenous sildenafil acutely improves pulmonary blood flow and cardiac output in these 
patients, while others have demonstrated that sildenafil improves exertional tolerance and 
myocardial performance.16,17,27,28 However, there are important safety concerns associated 
with sildenafil drug accumulation in children. The STARTS trial demonstrated increased 
mortality associated with medium or high dose oral sildenafil when compared to low dose 
therapy.15 These findings prompted the U.S. Food and Drug Administration to issue a safety 
warning recommending against use of sildenafil in children.29 This regulatory action has 
been contentious and the European Medicines Agency reviewed the same data yet approved 
sildenafil for pediatric use at low doses (10mg three times daily for patients < 20kg and 
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20mg three times daily for patients > 20kg).30 Despite difficulties in interpreting the 
STARTS trial results, the findings highlight the critical importance of dosing adjustments in 
populations with delayed sildenafil clearance.
Although our study focused on intravenous sildenafil, if our hypothesized mechanism of 
reduced biliary clearance of des-methyl-sildenafil is accurate, then findings may also apply 
to oral dosing. In healthy adults, oral sildenafil is well absorbed but undergoes significant 
first pass metabolism with a reported bioavailability ranging from 25%–63%.22 Peak levels 
are seen 30 – 120 minutes (median 60min) after oral dosing (versus 20min after intravenous 
dosing in the present study) and the recommended intravenous dose is half the oral dose. 
Our data suggest that a child with significantly elevated Fontan pressures receiving “low 
dose” oral sildenafil could be exposed to drug levels (combined sildenafil + des-methyl-
sildenafil) corresponding to higher doses. Reassuringly in the STARTS trial, mortality was 
increased only in the subset of children with idiopathic pulmonary hypertension. There are 
limited data for comparison of sildenafil clearance and volume between similar populations 
after oral and intravenous doses and PK and longer term efficacy studies are needed to 
evaluate both oral and intravenous sildenafil in Fontan subjects.
There are important limitations to this analysis. The sample size was relatively small and 
because this study was conducted in children, we employed a sparse sampling strategy with 
a median of 4 sildenafil samples per child. Sparse sampling is considered an appropriate 
approach to PK analysis in children where blood draws must be limited and we used a 
sampling and population PK approach that has been endorsed by both the U.S. FDA and the 
EMA.23–26,31,32 Another limitation is that the study population included patients with 
differing surgical anatomy (approximately half were status post stage II surgery and the 
remainder status post stage III surgery). Surgical stage uniquely affects physiology, however 
we did not detect a covariate effect of surgical stage on pharmacokinetic parameters during 
model development, after accounting for hepatic pressures. Finally, a two compartment 
model for sildenafil and one compartment model for des-methyl-sildenafil described the data 
appropriately, with precise model parameters (model estimates nearly identical to bootstrap 
estimates) and good model performance (good overlap of observed and simulated data on 
visual predictive checks). However, there was under prediction of the highest observed des-
methyl-sildenafil concentrations, occurring in stage III children. This likely resulted from 
the inability to incorporate inter-individual variability in volume of distribution of des-
methyl-sildenafil in this model.
In conclusion, the major findings of this analysis include similar weight normalized 
sildenafil clearance in children with palliated single ventricle heart defects when compared 
to healthy adult subjects and neonates. Volume of distribution and half-life were also similar 
to healthy adults, but when compared to neonates, volume of distribution was almost five-
fold lower resulting in a much shorter half-life of 2.9 hours (versus 48–56 hours for 
neonates). Notably we demonstrate an inverse relationship between hepatic pressure and 
clearance of des-methyl-sildenafil with estimated exposures approximately 50% greater in 
those with hepatic pressures ≥ 10mm Hg when compared to children with hepatic pressures 
< 10mm Hg. These data highlight the critical importance of pharmacokinetic analyses in 
patient populations with unique physiology, particularly because higher doses of sildenafil 
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have been associated with increased mortality in previous studies in children. In our opinion 
there is a critical need for PK, and longer-term safety and efficacy studies in single ventricle 
patients for sildenafil as well as other drugs that undergo hepatic metabolism.
Supplementary Material
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Figure 1. Concentration-time profiles
SIL = sildenafil; DMS = desmethylsildenafil; A, C = linear y-axis scale; B, D = log y-scale; 
circles = surgical stage 2; triangles = surgical stage 3.
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Figure 2. Final structural PK model
SIL = sildenafil; DMS = desmethylsildenafil; C1 = sildenafil central compartment; C2 = 
sildenafil peripheral compartment; CL12 = sildenafil intercompartmental clearance; C3 = 
DMS central compartment; CLSIL-to-DMS = sildenafil clearance (conversion to DMS); 
CLDMS = metabolite (DMS) clearance.
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Figure 3. Predicted total exposures in the study population with and without dose reduction for 
hepatic pressures >10 mm Hg
HP = hepatic pressure; A–C = single dose of 0.35 mg/kg; D–F = single dose of 0.35 mg/kg 
for HP <10 mm Hg and 0.25 mg/kg for HP ≥10 mm Hg; Circles = DMS; Triangles = SIL; 
Diamonds = AUCTOTAL = AUCSIL + AUCDMS/2.
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